Voy app for weight loss with GLP-1 medication
Part of Hormones & metabolism clinical trials.
This trial tests whether using the Voy app can help people who are already taking a GLP-1 or GIP/GLP-1 weight loss medication lose more weight and improve their health. If you're eligible, the app will be added to your current treatment plan to see if it makes a difference.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a BMI of 30 or more, or a BMI of 27 or more with a weight-related health issue (like high blood pressure, sleep apnea, or PCOS).
- You are already taking a GLP-1 or GIP/GLP-1 medication (like Wegovy, Mounjaro, or Ozempic) for weight loss.
- You have a smartphone that runs on iOS 16 or Android 8 or later.
- You agree not to use any other weight loss programs, supplements, or medications during the study.
- You are not pregnant, planning to get pregnant, or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how GLP-1 medications (like Ozempic or Wegovy) combined with behavioral coaching through Noom affect weight loss and metabolic health over 12 months. You may qualify if you're interested in weight loss and willing to commit to a program for a year.
This study tests a 6-month behavioral program (including exercise, diet, and mindfulness) designed to help you keep weight off after stopping GLP-1 or similar weight-loss medications. It's for people who have already lost at least 15% of their body weight and stopped or are stopping these medications.
This study tests a new weight loss program designed specifically for young adults ages 18 to 40. You will use a smartphone app to help you lose weight, and the study will see if the program works well for people in your age group.
This trial tests a mobile app that helps you track your diet to manage your weight. It is designed for people with heart failure who are overweight and have recently been in the hospital for their condition.
This study uses a smartphone app and a wearable device to help you manage your weight and health risks. It is for people with a body mass index (BMI) between 27 and 42 who are ready to make healthy changes.
This study tests a natural supplement (elénzia CONTROL®) to help with weight loss and metabolic health. Researchers want to see if it works for people who have never used GLP-1 medications or who have stopped using them.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.